NASDAQ:LPCN Lipocine (LPCN) Stock Forecast, Price & News $2.92 +0.09 (+3.18%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$2.79▼$3.0350-Day Range$2.83▼$5.1052-Week Range$2.76▼$10.33Volume15,259 shsAverage Volume68,758 shsMarket Capitalization$15.53 millionP/E RatioN/ADividend YieldN/APrice Target$68.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Lipocine MarketRank™ ForecastAnalyst Rating0.00 Rating ScoreUpside/Downside2,228.8% Upside$68.00 Price TargetShort InterestHealthy2.53% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.70) to ($1.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.54 out of 5 starsMedical Sector887th out of 976 stocksPharmaceutical Preparations Industry408th out of 447 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $68.00, Lipocine has a forecasted upside of 2,228.8% from its current price of $2.92.Amount of Analyst CoverageLipocine has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.53% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently increased by 52.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPCN. Previous Next 2.4 News and Social Media Coverage News SentimentLipocine has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lipocine this week, compared to 0 articles on an average week.Search Interest6 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lipocine to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 8.99% of the stock of Lipocine is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lipocine are expected to grow in the coming year, from ($2.70) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipocine has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lipocine (NASDAQ:LPCN) StockLipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.Read More LPCN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LPCN Stock News HeadlinesSeptember 28, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)September 19, 2023 | finance.yahoo.comLipocine to Present at the Cantor Fitzgerald Global Healthcare ConferenceOctober 3, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!August 17, 2023 | stocknews.comLooking for a Value Investment? Check out These 3 Pharma StocksAugust 16, 2023 | finance.yahoo.comLPCN: Trial Results Improve OutlookAugust 10, 2023 | finance.yahoo.comLipocine Announces Financial Results for the Second Quarter Ended June 30, 2023July 31, 2023 | finance.yahoo.comLPCN: 1148 Shows Muscle Loss ReversalJuly 27, 2023 | benzinga.comWhy Lipocine Stock Is Moving Higher Today?October 3, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!July 27, 2023 | investorplace.comWhy Is Lipocine (LPCN) Stock Up 32% Today?June 14, 2023 | finance.yahoo.comLipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual ConferenceJune 7, 2023 | finance.yahoo.comLipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023May 16, 2023 | msn.comLipocine stock dips after bridging study data of LPCN 1154 for postpartum depressionMay 16, 2023 | finance.yahoo.comPositive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of DepressionMay 12, 2023 | msn.comRecap: Lipocine Q1 EarningsMay 11, 2023 | apnews.comLipocine: Q1 Earnings SnapshotMay 11, 2023 | finance.yahoo.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2023April 3, 2023 | finance.yahoo.comFirst Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154March 16, 2023 | finance.yahoo.comLPCN: 2022 Operational & Financial UpdateMarch 10, 2023 | finance.yahoo.comLipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common StockMarch 10, 2023 | finance.yahoo.comLipocine Announces Financial Results for the Year Ended December 31, 2022January 16, 2023 | finance.yahoo.comIs Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?January 5, 2023 | finance.yahoo.comLipocine to Present at Biotech ShowcaseDecember 19, 2022 | finance.yahoo.comLipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated CirrhosisNovember 9, 2022 | finance.yahoo.comLipocine Announces Financial Results for the Third Quarter Ended September 30, 2022November 3, 2022 | finance.yahoo.comLipocine Announces Senior Leadership Appointments to Advance its CNS-Focused PipelineOctober 11, 2022 | finance.yahoo.comLipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference - Yahoo FinanceSee More Headlines Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address LPCN Company Calendar Last Earnings8/10/2023Today10/03/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LPCN CUSIPN/A CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees15Year Founded1997Price Target and Rating Average Stock Price Forecast$68.00 High Stock Price Forecast$68.00 Low Stock Price Forecast$68.00 Forecasted Upside/Downside+2,277.6%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($2.3807) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,760,000.00 Net MarginsN/A Pretax Margin-21,921.82% Return on Equity-36.05% Return on Assets-34.09% Debt Debt-to-Equity RatioN/A Current Ratio14.82 Quick Ratio14.82 Sales & Book Value Annual Sales$500,000.00 Price / Sales30.43 Cash FlowN/A Price / Cash FlowN/A Book Value$6.85 per share Price / Book0.42Miscellaneous Outstanding Shares5,320,000Free Float5,040,000Market Cap$15.22 million OptionableOptionable Beta1.04 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Mahesh V. Patel Ph.D. (Age 66)Co-Founder, Interim Principal Financial Officer, Director, Pres & CEO Comp: $598.91kMs. Krista Fogarty (Age 55)Principal Accounting Officer & Corp. Controller Comp: $268.12kDr. Nachiappan Chidambaram Ph.D. (Age 53)Sr. VP of R&D Comp: $311.17kMr. Logan Morse (Age 53)VP of Sales, Marketing & Operations Mr. Morgan R. Brown CPA (Age 55)CPA, M.B.A., MBA, Corp. Sec. Key CompetitorsCelyad OncologyNASDAQ:CYADNanoViricidesNYSE:NNVCKazia TherapeuticsNASDAQ:KZIAVascular BiogenicsNASDAQ:VBLTProMIS NeurosciencesNASDAQ:PMNView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 900 shares on 8/15/2023Ownership: 0.000%State Street CorpSold 298,007 shares on 8/14/2023Ownership: 0.350%Geode Capital Management LLCSold 781,233 shares on 8/11/2023Ownership: 0.939%Kestra Advisory Services LLCSold 267,215 shares on 8/11/2023Ownership: 0.321%Renaissance Technologies LLCSold 187,952 shares on 8/11/2023Ownership: 0.200%View All Insider TransactionsView All Institutional Transactions LPCN Stock - Frequently Asked Questions What is Lipocine's stock price forecast for 2023? 0 brokers have issued 12-month price objectives for Lipocine's shares. Their LPCN share price forecasts range from $68.00 to $68.00. On average, they anticipate the company's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 2,277.6% from the stock's current price. View analysts price targets for LPCN or view top-rated stocks among Wall Street analysts. How have LPCN shares performed in 2023? Lipocine's stock was trading at $6.7626 at the beginning of the year. Since then, LPCN stock has decreased by 57.7% and is now trading at $2.86. View the best growth stocks for 2023 here. Are investors shorting Lipocine? Lipocine saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 130,600 shares, an increase of 52.0% from the August 31st total of 85,900 shares. Based on an average daily volume of 163,900 shares, the short-interest ratio is presently 0.8 days. Currently, 2.5% of the company's shares are short sold. View Lipocine's Short Interest. When is Lipocine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our LPCN earnings forecast. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) issued its quarterly earnings results on Thursday, August, 10th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.04. When did Lipocine's stock split? Shares of Lipocine reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX). What is Lipocine's stock symbol? Lipocine trades on the NASDAQ under the ticker symbol "LPCN." How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lipocine's stock price today? One share of LPCN stock can currently be purchased for approximately $2.86. How much money does Lipocine make? Lipocine (NASDAQ:LPCN) has a market capitalization of $15.22 million and generates $500,000.00 in revenue each year. The specialty pharmaceutical company earns $-10,760,000.00 in net income (profit) each year or ($2.3807) on an earnings per share basis. How can I contact Lipocine? Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388. This page (NASDAQ:LPCN) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.